<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25185241</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>06</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1569-8041</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>25</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title>
                <ISOAbbreviation>Ann. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pancreatic cancer risk after treatment of Hodgkin lymphoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2073-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdu287</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although elevated risks of pancreatic cancer have been observed in long-term survivors of Hodgkin lymphoma (HL), no prior study has assessed the risk of second pancreatic cancer in relation to radiation dose and specific chemotherapeutic agents.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">We conducted an international case-control study within a cohort of 19 882 HL survivors diagnosed from 1953 to 2003 including 36 cases and 70 matched controls.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Median ages at HL and pancreatic cancer diagnoses were 47 and 60.5 years, respectively; median time to pancreatic cancer was 19 years. Pancreatic cancer risk increased with increasing radiation dose to the pancreatic tumor location (Ptrend = 0.005) and increasing number of alkylating agent (AA)-containing cycles of chemotherapy (Ptrend = 0.008). The odds ratio (OR) for patients treated with both subdiaphragmatic radiation (≥10 Gy) and ≥6 AA-containing chemotherapy cycles (13 cases, 6 controls) compared with patients with neither treatment was 17.9 (95% confidence interval 3.5-158). The joint effect of these two treatments was significantly greater than additive (P = 0.041) and nonsignificantly greater than multiplicative (P = 0.29). Especially high risks were observed among patients receiving ≥8400 mg/m(2) of procarbazine with nitrogen mustard or ≥3900 mg/m(2) of cyclophosphamide.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study demonstrates for the first time that both radiotherapy and chemotherapy substantially increase pancreatic cancer risks among HL survivors treated in the past. These findings extend the range of nonhematologic cancers associated with chemotherapy and add to the evidence that the combination of radiotherapy and chemotherapy can lead to especially large risks.</AbstractText>
                <CopyrightInformation>Published by Oxford University Press on behalf of the European Society for Medical Oncology 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dores</LastName>
                    <ForeName>G M</ForeName>
                    <Initials>GM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda Department of Veterans Affairs Medical Center, Oklahoma City, USA doresg@mail.nih.gov.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Curtis</LastName>
                    <ForeName>R E</ForeName>
                    <Initials>RE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Leeuwen</LastName>
                    <ForeName>F E</ForeName>
                    <Initials>FE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology and Biostatistics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stovall</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hall</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lynch</LastName>
                    <ForeName>C F</ForeName>
                    <Initials>CF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology, University of Iowa, Iowa City, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smith</LastName>
                    <ForeName>S A</ForeName>
                    <Initials>SA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weathers</LastName>
                    <ForeName>R E</ForeName>
                    <Initials>RE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Storm</LastName>
                    <ForeName>H H</ForeName>
                    <Initials>HH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Prevention and Documentation, Danish Cancer Society, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hodgson</LastName>
                    <ForeName>D C</ForeName>
                    <Initials>DC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Toronto, Toronto, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kleinerman</LastName>
                    <ForeName>R A</ForeName>
                    <Initials>RA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Joensuu</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Johannesen</LastName>
                    <ForeName>T B</ForeName>
                    <Initials>TB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Registry of Norway, Oslo, Norway.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Andersson</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Holowaty</LastName>
                    <ForeName>E J</ForeName>
                    <Initials>EJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaijser</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Epidemiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pukkala</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki and School of Health Sciences, University of Tampere, Tampere, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vaalavirta</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fossa</LastName>
                    <ForeName>S D</ForeName>
                    <Initials>SD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Oslo University Hospital and University of Oslo, Oslo, Norway.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Langmark</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Registry of Norway, Oslo, Norway.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Travis</LastName>
                    <ForeName>L B</ForeName>
                    <Initials>LB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Rochester Medical Center, Rochester, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fraumeni</LastName>
                    <ForeName>J F</ForeName>
                    <Initials>JF</Initials>
                    <Suffix>Jr</Suffix>
                    <AffiliationInfo>
                        <Affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aleman</LastName>
                    <ForeName>B M</ForeName>
                    <Initials>BM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morton</LastName>
                    <ForeName>L M</ForeName>
                    <Initials>LM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gilbert</LastName>
                    <ForeName>E S</ForeName>
                    <Initials>ES</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30 CA086862</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 ES005605</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Ann Oncol</MedlineTA>
            <NlmUniqueID>9007735</NlmUniqueID>
            <ISSNLinking>0923-7534</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004307" MajorTopicYN="N">Dose-Response Relationship, Radiation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006689" MajorTopicYN="N">Hodgkin Disease</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009381" MajorTopicYN="N">Neoplasms, Radiation-Induced</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>
                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
                <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011878" MajorTopicYN="N">Radiotherapy</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Hodgkin lymphoma</Keyword>
            <Keyword MajorTopicYN="N">chemotherapy</Keyword>
            <Keyword MajorTopicYN="N">pancreatic cancer</Keyword>
            <Keyword MajorTopicYN="N">radiotherapy</Keyword>
            <Keyword MajorTopicYN="N">second cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>9</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>9</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>6</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25185241</ArticleId>
            <ArticleId IdType="pii">mdu287</ArticleId>
            <ArticleId IdType="doi">10.1093/annonc/mdu287</ArticleId>
            <ArticleId IdType="pmc">PMC4176454</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2000 Jun;18(12):2435-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10856104</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2007 Apr 20;25(12):1489-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17372278</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2002 Aug 15;20(16):3484-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12177110</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2003 Jul 23;290(4):465-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12876089</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Carcinogenesis. 1991 Oct;12(10):1751-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1934255</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 1994 Nov 1;59(3):327-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7927937</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Radiat Oncol Biol Phys. 1997 Jan 1;37(1):67-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9054878</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Stat Med. 1999 Mar 30;18(6):695-706</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10204198</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Epidemiol. 2006 Mar 15;163(6):502-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16421239</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Radiat Res. 2006 Jul;166(1 Pt 2):141-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16808603</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Radiat Res. 2007 Jul;168(1):1-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17722996</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2009 Apr 16;113(16):3679-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19234144</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1420-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19931732</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2010 Aug 12;363(7):640-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20818855</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):92-101</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22028399</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2012 Jun 5;156(11):757-66, W-260</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22665813</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2012 Jul 10;30(20):2552-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22665546</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):224-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22795729</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2012 Sep 1;380(9844):836-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22835602</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):451-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22682810</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2013 Jan;63(1):11-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23335087</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2013 Sep 20;31(27):3369-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23980092</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):854-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23790512</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2002 Feb 6;94(3):182-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11830608</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>